Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-21-004029
Filing Date
2021-06-03
Accepted
2021-06-03 17:27:48
Documents
2
Period of Report
2021-06-02

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 6295
2 POA UPDATED AUG '20 poamrogers_updated.txt EX-24 3485
  Complete submission text file 0001562180-21-004029.txt   11135
Mailing Address C/O KERYX BIOPHARMACEUTICALS INC ONE MARINA PARK DRIVE BOSTON MA 02210
Business Address
ROGERS MICHAEL W (Reporting) CIK: 0001244159 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36352 | Film No.: 21993690

Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Issuer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations